RA ℞: T-Cell Co-Stimulation Blockade

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naïve patients with rheumatoid arthritis (RA) initiating abatacept in clinic
link.springer.com

Abatacept may benefit ACPA-negative undifferentiated arthritis

Abatacept therapy prevented further progression of disease in 18 of 20 patients, but many patients needed additional therapy to maintain the halt in disease…
mdedge.com

Comments are closed.